Is the telomere length associated with neurocognitive disabilities in HIV-1-infected subjects?
AUTOR(ES)
Araújo, Marilia Ladeira de, Duarte, Wellington, Oliveira, Augusto César Penalva de, Gascón, Maria Rita Polo, Fonseca, Luiz Augusto Marcondes, Paiva, Raquel de Melo Alves, Santana, Bárbara, Calado, Rodrigo Tocantins, Casseb, Jorge
FONTE
Rev. Inst. Med. trop. S. Paulo
DATA DE PUBLICAÇÃO
23/04/2018
RESUMO
ABSTRACT Objective: We evaluated the association between cognitive deficits and leukocyte telomere length (LTL) in HIV-1-infected individuals. Design: 73 HIV-1-infected patients undergoing neuropsychological evaluation and 91 healthy controls were included in this study. Fifteen HIV-1 positive patients did not have cognitive disorders whereas 26 had asymptomatic neurocognitive disorder (ANI), 13 presented mild to moderate neurocognitive disorder (MND), and 10 had HIV-associated dementia (HAD). Methods: DNA from the peripheral blood of HIV-1-infected patients was used for measurement of telomere length by real-time PCR. HIV-1 viral load was determined in blood. Results: LTL decreased with age in healthy controls (p=0.0001). Regardless of the HIV status, age-matched LTL from HIV patients, including those with ANI and MND, were shortened in comparison to the healthy control group (p=0.0073); however, no association was found among the HIV-1-infected individuals with cognitive deficits (p=0.01). In addition, no gender-related association with LTL was observed (p=0.80), smoking, physical exercise, and plasma viral load were not correlated to telomere length (p=0.66). Conclusions: We concluded that leukocyte telomere length may not be a marker of cellular senescence in individuals with HIV infection and neurocognitive disorders.
Documentos Relacionados
- Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects
- Response of HIV-associated proteinuria to antiretroviral therapy in HIV-1-infected children
- Thyroid evaluation in HIV-1-infected patients
- CD8+ T-Cell Gamma Interferon Production Specific for Human Immunodeficiency Virus Type 1 (HIV-1) in HIV-1-Infected Subjects
- Serum beta 2-microglobulin levels in asymptomatic HIV-1-infected subjects during long-term zidovudine treatment.